| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
172.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
84,560 |
206,385 |
272,181 |
454,395 |
| Total Sell Value |
$393,343 |
$830,960 |
$965,155 |
$2,986,647 |
| Total People Sold |
6 |
6 |
7 |
9 |
| Total Sell Transactions |
7 |
20 |
25 |
42 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Velleca Mark A. |
|
– • – |
2021-05-25 |
4 |
OE |
$0.39 |
$7,800 |
D/D |
20,000 |
61,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-05-13 |
4 |
AS |
$20.54 |
$205,413 |
D/D |
(10,000) |
41,000 |
|
-27% |
|
| Velleca Mark A. |
|
– • – |
2021-05-13 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
51,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-05-12 |
4 |
AS |
$20.07 |
$200,691 |
D/D |
(10,000) |
41,000 |
|
-28% |
|
| Velleca Mark A. |
|
– • – |
2021-05-12 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
51,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-05-11 |
4 |
AS |
$19.10 |
$190,997 |
D/D |
(10,000) |
41,000 |
|
-27% |
|
| Velleca Mark A. |
|
– • – |
2021-05-11 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
51,000 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-05-10 |
4 |
OE |
$0.30 |
$3,000 |
D/D |
10,000 |
53,300 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-04-22 |
4 |
AS |
$22.07 |
$331,100 |
D/D |
(15,000) |
43,300 |
|
-33% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-04-22 |
4 |
OE |
$0.39 |
$5,850 |
D/D |
15,000 |
58,300 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-04-15 |
4 |
AS |
$24.96 |
$249,631 |
D/D |
(10,000) |
41,000 |
|
-43% |
|
| Velleca Mark A. |
|
– • – |
2021-04-15 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
51,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-04-14 |
4 |
AS |
$24.53 |
$245,272 |
D/D |
(10,000) |
41,000 |
|
-42% |
|
| Velleca Mark A. |
|
– • – |
2021-04-14 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
51,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-04-13 |
4 |
AS |
$23.89 |
$238,865 |
D/D |
(10,000) |
41,000 |
|
-44% |
|
| Velleca Mark A. |
|
– • – |
2021-04-13 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
51,000 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-03-23 |
4 |
AS |
$21.94 |
$329,060 |
D/D |
(15,000) |
43,300 |
|
-20% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-03-23 |
4 |
OE |
$0.39 |
$5,850 |
D/D |
15,000 |
58,300 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2021-03-03 |
4 |
OE |
$3.72 |
$11,160 |
D/D |
3,000 |
25,000 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
AS |
$22.95 |
$344,192 |
D/D |
(15,000) |
43,300 |
|
-15% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2021-03-02 |
4 |
OE |
$0.39 |
$23,219 |
D/D |
15,000 |
58,300 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-02-18 |
4 |
AS |
$26.02 |
$260,152 |
D/D |
(10,000) |
41,000 |
|
-13% |
|
| Velleca Mark A. |
|
– • – |
2021-02-18 |
4 |
OE |
$3.72 |
$37,200 |
D/D |
10,000 |
51,000 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2021-02-17 |
4 |
AS |
$27.59 |
$276,433 |
D/D |
(10,000) |
41,000 |
|
-16% |
|
| Velleca Mark A. |
|
– • – |
2021-02-17 |
4 |
OE |
$3.72 |
$37,200 |
D/D |
10,000 |
51,000 |
|
- |
|
334 Records found
|
|
Page 6 of 14 |
|
|
0.15 (3.21%) 
